An Open-Label Trial of Escitalopram in Children and Adolescents with Social Anxiety Disorder
- 1 December 2007
- journal article
- research article
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 17 (6) , 751-760
Abstract
Social anxiety disorder (SAD) is a highly prevalent and disabling disorder in children and adolescents. This study was designed to evaluate the efficacy and safety of a highly potent and selective serotonin reuptake inhibitor, escitalopram, in the treatment of SAD in children and adolescents. Twenty outpatients with a primary diagnosis of SAD were treated in a 12-week open trial with escitalopram. The primary outcome variable was the change from baseline to end point in Clinical Global Impression–Improvement scale (CGI-I). Secondary efficacy measures included the CGI–Severity scale (CGI-S), the Social Phobia and Anxiety Inventory for Children (SPAI-C), the Screen for Child and Anxiety Related Emotional Disorders (SCARED)–Child and Parent version, and The Youth Quality of Life Instrument–Research Version (Y-QOL-R). On the CGI-I scale, 13 of 20 patients (65%) had a score ≤2, meaning response to treatment. All symptomatic and quality of life measures showed improvements from baseline to week 12, with large effect sizes ranging from 0.9 to 1.9 (all p < 0.001). Escitalopram was generally well-tolerated. These results suggest that escitalopram may be an effective and safe treatment for pediatric SAD. Future double-blind, placebo-controlled, randomized clinical trials are warranted.Keywords
This publication has 31 references indexed in Scilit:
- Prevalence of Child and Adolescent Psychiatric Disorders in Southeast BrazilJournal of the American Academy of Child & Adolescent Psychiatry, 2004
- Escitalopram in the treatment of generalized anxiety disorder: Double-blind, placebo controlled, flexible-dose studyDepression and Anxiety, 2004
- Fluoxetine for the Treatment of Childhood Anxiety DisordersJournal of the American Academy of Child & Adolescent Psychiatry, 2003
- Fixed-Dose Trial of the Single Isomer SSRI Escitalopram in Depressed OutpatientsThe Journal of Clinical Psychiatry, 2002
- Combined Psychoeducation and Treatment with Selective Serotonin Reuptake Inhibitors for Youth with Generalized Social Anxiety DisorderJournal of Child and Adolescent Psychopharmacology, 2002
- Sertraline in Children and Adolescents With Social Anxiety Disorder: An Open TrialJournal of the American Academy of Child & Adolescent Psychiatry, 2001
- Psychometric Properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): A Replication StudyJournal of the American Academy of Child & Adolescent Psychiatry, 1999
- The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale Construction and Psychometric CharacteristicsJournal of the American Academy of Child & Adolescent Psychiatry, 1997
- A new inventory to assess childhood social anxiety and phobia: The Social Phobia and Anxiety Inventory for Children.Psychological Assessment, 1995
- Fluoxetine for Childhood Anxiety DisordersJournal of the American Academy of Child & Adolescent Psychiatry, 1994